The utility of selecting ODA in order to obtain less nephrotoxicity in comparison with TDA is therefore not established when the treatment is prolonged. In clinical use, the choice of the dosage regimen is not clear-cut, and both expected efficacy and expected toxicity must be taken into account in order to obtain an overall optimisation of each patient's therapy.
Augusto BaffaRonaldo Ribeiro GoldschmidtJorge de Abreu SoaresCláudia Ferlin
MA Pérez-ChavarríaHugo Hidalgo-SilvaFrancisco J. Ocampo‐Torres
Anas KabboriJilali AntariRadouane IqdourZine El Abidine El Morjani